Home » Stocks » AZRX

AzurRx BioPharma, Inc. (AZRX)

Stock Price: $0.778 USD -0.042 (-5.11%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $0.775 -0.003 (-0.39%) May 11, 5:20 AM
Market Cap 57.91M
Revenue (ttm) n/a
Net Income (ttm) -32.67M
Shares Out 74.44M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $0.778
Previous Close $0.820
Change ($) -0.042
Change (%) -5.11%
Day's Open 0.800
Day's Range 0.775 - 0.820
Day's Volume 859,143
52-Week Range 0.650 - 2.630

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Reopening penny stocks that investors are watching right now The post 3 Reopening Penny Stocks to Watch in April 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other stocks mentioned: BIOL, WRAP
2 weeks ago - PennyStocks

DELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of t...

3 weeks ago - GlobeNewsWire

AzurRx BioPharma Inc (NASDAQ: AZRX) has initiated Phase 2 RESERVOIR trial evaluating oral formulation of micronized niclosamide (FW-1022) for the treatment of COVID-19 related gastrointestinal (GI) infe...

1 month ago - Benzinga

“RESERVOIR” trial to evaluate niclosamide's ability to target SARS-CoV-2 in the GI tract

1 month ago - GlobeNewsWire

DELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of t...

1 month ago - GlobeNewsWire

AzurRx to Host Conference Call and Live Audio Webcast Today, Wednesday, March 31, 2021 at 4:30 p.m. ET AzurRx to Host Conference Call and Live Audio Webcast Today, Wednesday, March 31, 2021 at 4:30 p.m. ET

1 month ago - GlobeNewsWire

Top-line data expected in Q2 2021 Top-line data expected in Q2 2021

1 month ago - GlobeNewsWire

DELRAY BEACH, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant ...

2 months ago - GlobeNewsWire

AzurRx Chairman and CEO, James Sapirstein, to participate in panel discussion on potential developmental therapeutics for SARS-CoV-2 infection AzurRx Chairman and CEO, James Sapirstein, to participate i...

2 months ago - GlobeNewsWire

DELRAY BEACH, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant ...

2 months ago - GlobeNewsWire

Former Chairman Edward J. Borkowski to continue as the lead independent director on the board Former Chairman Edward J. Borkowski to continue as the lead independent director on the board

2 months ago - GlobeNewsWire

DELRAY BEACH, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant t...

2 months ago - GlobeNewsWire

Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. ...

Other stocks mentioned: USNA, ABCL, CGIX
3 months ago - Benzinga

Phase 2 Study of oral niclosamide planned for 1H 2021

3 months ago - GlobeNewsWire

DELRAY BEACH, Fla., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant t...

3 months ago - GlobeNewsWire

$8 Million Offering to Fuel Acquisitions and Clinical Studies Leading Therapeutic for COVID-19 Related Gastrointestinal Infections. MS1819 a Better Mousetrap vs Porcine Competitors.

3 months ago - Seeking Alpha

DELRAY BEACH, Fla., Jan. 28, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant t...

3 months ago - GlobeNewsWire

AzurRx BioPharma (NASDAQ: AZRX) shares are trading higher Friday amid a surge in session volume for the day. On Thursday, the company announced it has started dosing in the mid-stage cystic fibrosis stu...

3 months ago - Benzinga

AzurRX (AZRX) is developing its pipeline candidate, MS1819, as monotherapy as well in combination with standard of care for treating exocrine pancreatic insufficiency in patients with cystic fibrosis.

3 months ago - Zacks Investment Research

DELRAY BEACH, Fla., Jan. 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of ta...

3 months ago - GlobeNewsWire

DELRAY BEACH, Fla., Jan. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant t...

4 months ago - GlobeNewsWire

DELRAY BEACH, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies fo...

4 months ago - GlobeNewsWire

DELRAY BEACH, Fla., Jan. 04, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of non-systemic therapies for gastroin...

4 months ago - GlobeNewsWire

DELRAY BEACH, Fla., Nov. 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies f...

5 months ago - GlobeNewsWire

Potential to add additional study arm utilizing immediate release capsules

5 months ago - GlobeNewsWire

DELRAY BEACH, Fla., Nov. 10, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies f...

6 months ago - GlobeNewsWire

NEW YORK, Oct. 29, 2020 (GLOBE NEWSWIRE) -- via InvestorWire -- AzurRx BioPharma, Inc. ( NASDAQ: AZRX ) (“AzurRx” or the “Company”), a New York-based biopharmaceutical company specializing in the develo...

6 months ago - GlobeNewsWire

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastro...

6 months ago - GlobeNewsWire

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastroi...

6 months ago - GlobeNewsWire

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastr...

8 months ago - GlobeNewsWire

NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastr...

8 months ago - GlobeNewsWire

NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gast...

8 months ago - GlobeNewsWire

NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gast...

8 months ago - GlobeNewsWire

Management to discuss the interim results on call scheduled for today, August 11, 2020, at 4:30 p.m. Eastern Time

8 months ago - GlobeNewsWire

NEW YORK, July 22, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...

9 months ago - PRNewsWire

NEW YORK, July 22, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastr...

9 months ago - GlobeNewsWire

NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ: AZRX ), (“AzurRx” or the “Company”), today announced that on July 16, 2020, it entered into a Convertible Preferred Stock and War...

9 months ago - GlobeNewsWire

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gast...

1 year ago - GlobeNewsWire

NEW YORK, April 21, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gas...

1 year ago - GlobeNewsWire

NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant  therapies for g...

1 year ago - GlobeNewsWire

Seasoned veteran with decades of strategic and global leadership experience Seasoned veteran with decades of strategic and global leadership experience

1 year ago - GlobeNewsWire

NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gast...

1 year ago - GlobeNewsWire

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastr...

1 year ago - GlobeNewsWire

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastr...

1 year ago - GlobeNewsWire

NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for gastroint...

1 year ago - GlobeNewsWire

NEW YORK, Jan. 03, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gast...

1 year ago - GlobeNewsWire

NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastr...

1 year ago - GlobeNewsWire

NEW YORK, Oct. 22, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gast...

1 year ago - GlobeNewsWire

About AZRX

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-... [Read more...]

Industry
Biotechnology
IPO Date
Oct 11, 2016
Stock Exchange
NASDAQ
Ticker Symbol
AZRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for AZRX stock is "Buy." The 12-month stock price forecast is 3.50, which is an increase of 349.87% from the latest price.

Price Target
$3.50
(349.87% upside)
Analyst Consensus: Buy